UK Creutzfeldt Jakob Disease Market

ID: MRFR/HC/52723-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
UK Creutzfeldt-Jakob Disease Market Research Report: Size, Share, Trend Analysis By Types (Sporadic Creutzfeldt-Jakob Disease, Familial Creutzfeldt-Jakob Disease, Iatrogenic Creutzfeldt-Jakob Disease, Variant Creutzfeldt-Jakob Disease), By Diagnosis Method (Electroencephalogram, Magnetic Resonance Imaging, Cerebrospinal Fluid Tests, Brain Biopsy), By Treatment Approach (Supportive Care, Experimental Therapies, Symptomatic Treatment) and By End Users (Hospitals, Diagnostic Laboratories, Research Institutes) - Growth Outlook & Industry Forecast 2025 To 2035
UK Creutzfeldt Jakob Disease Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.88%
2024 Market Size$ 36 Million
2025 Market Size$ 38.12 Million
2035 Market Size$ 67.5 Million
Key Players
Grifols
Kedrion
Octapharma
CSL Behring
Biotest AG
Shire
Opportunities
  • Rising Incidence Rates
  • Regulatory Support for Research
  • Increased Public Health Initiatives
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Food, Beverages & Nutrition, BY Type (USD Million)
      1. 4.1.1 Sporadic Creutzfeldt-Jakob Disease
      2. 4.1.2 Familial Creutzfeldt-Jakob Disease
      3. 4.1.3 Iatrogenic Creutzfeldt-Jakob Disease
      4. 4.1.4 Variant Creutzfeldt-Jakob Disease
    2. 4.2 Food, Beverages & Nutrition, BY Diagnosis Method (USD Million)
      1. 4.2.1 Electroencephalogram
      2. 4.2.2 Magnetic Resonance Imaging
      3. 4.2.3 Cerebrospinal Fluid Tests
      4. 4.2.4 Brain Biopsy
    3. 4.3 Food, Beverages & Nutrition, BY Treatment Approach (USD Million)
      1. 4.3.1 Supportive Care
      2. 4.3.2 Experimental Therapies
      3. 4.3.3 Symptomatic Treatment
    4. 4.4 Food, Beverages & Nutrition, BY End User (USD Million)
      1. 4.4.1 Hospitals
      2. 4.4.2 Diagnostic Laboratories
      3. 4.4.3 Research Institutes
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Food, Beverages & Nutrition
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Food, Beverages & Nutrition
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Grifols (ES)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Kedrion (IT)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Octapharma (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 CSL Behring (AU)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Biotest AG (DE)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Shire (IE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Baxter International (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Emergent BioSolutions (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 UK MARKET ANALYSIS BY TYPE
    3. 6.3 UK MARKET ANALYSIS BY DIAGNOSIS METHOD
    4. 6.4 UK MARKET ANALYSIS BY TREATMENT APPROACH
    5. 6.5 UK MARKET ANALYSIS BY END USER
    6. 6.6 KEY BUYING CRITERIA OF FOOD, BEVERAGES & NUTRITION
    7. 6.7 RESEARCH PROCESS OF MRFR
    8. 6.8 DRO ANALYSIS OF FOOD, BEVERAGES & NUTRITION
    9. 6.9 DRIVERS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    10. 6.10 RESTRAINTS IMPACT ANALYSIS: FOOD, BEVERAGES & NUTRITION
    11. 6.11 SUPPLY / VALUE CHAIN: FOOD, BEVERAGES & NUTRITION
    12. 6.12 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 (% SHARE)
    13. 6.13 FOOD, BEVERAGES & NUTRITION, BY TYPE, 2024 TO 2035 (USD Million)
    14. 6.14 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS METHOD, 2024 (% SHARE)
    15. 6.15 FOOD, BEVERAGES & NUTRITION, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Million)
    16. 6.16 FOOD, BEVERAGES & NUTRITION, BY TREATMENT APPROACH, 2024 (% SHARE)
    17. 6.17 FOOD, BEVERAGES & NUTRITION, BY TREATMENT APPROACH, 2024 TO 2035 (USD Million)
    18. 6.18 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 (% SHARE)
    19. 6.19 FOOD, BEVERAGES & NUTRITION, BY END USER, 2024 TO 2035 (USD Million)
    20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 UK MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Million)
      3. 7.2.3 BY TREATMENT APPROACH, 2025-2035 (USD Million)
      4. 7.2.4 BY END USER, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

UK Creutzfeldt Jakob Disease Market Segmentation

UK Creutzfeldt Jakob Disease Market By Type (USD Million, 2025-2035)

  • Sporadic Creutzfeldt-Jakob Disease
  • Familial Creutzfeldt-Jakob Disease
  • Iatrogenic Creutzfeldt-Jakob Disease
  • Variant Creutzfeldt-Jakob Disease

UK Creutzfeldt Jakob Disease Market By Diagnosis Method (USD Million, 2025-2035)

  • Electroencephalogram
  • Magnetic Resonance Imaging
  • Cerebrospinal Fluid Tests
  • Brain Biopsy

UK Creutzfeldt Jakob Disease Market By Treatment Approach (USD Million, 2025-2035)

  • Supportive Care
  • Experimental Therapies
  • Symptomatic Treatment

UK Creutzfeldt Jakob Disease Market By End User (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.